Patients with stage II-IIIB gastric cancer who underwent curative D@ gastrectomy were randomly assigned ( @:@ ) after surgery to receive adjuvant chemotherapy with capecitabine and oxaliplatin ( eight @-week cycles of oral capecitabine @ mg/m ( @ ) twice daily on days @-@ plus intravenous oxaliplatin @ mg/m ( @ ) on day @ ) for @ months or observation alone .